Discovery of RO7185876, a Highly Potent γ-Secretase Modulator (GSM) as a Potential Treatment for Alzheimer's Disease.

γ-Secretase (GS) is a key target for the potential treatment of Alzheimer's disease. While inhibiting GS led to serious side effects, its modulation holds a lot of potential to deliver a safe treatment. Herein, we report the discovery of a potent and selective gamma secretase modulator (GSM) (S)-3 (RO7185876), belonging to a novel chemical class, the triazolo-azepines. This compound demonstrates an excellent in vitro and in vivo DMPK profile. Furthermore, based on its in vivo efficacy in a pharmacodynamic mouse model and the outcome of the dose range finding (DRF) toxicological studies in two species, this compound was selected to undergo entry in human enabling studies (e.g., GLP toxicology and scale up activities).

[1]  J. Hardy,et al.  Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.

[2]  Jae Eun Ahn,et al.  Pharmacokinetic and Pharmacodynamic Effects of a γ‐Secretase Modulator, PF‐06648671, on CSF Amyloid‐β Peptides in Randomized Phase I Studies , 2019, Clinical pharmacology and therapeutics.

[3]  D. Kovacs,et al.  The many substrates of presenilin/γ-secretase. , 2011, Journal of Alzheimer's disease : JAD.

[4]  J. Trojanowski,et al.  A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. , 1991, Science.

[5]  D. Borchelt,et al.  Short Aβ peptides attenuate Aβ42 toxicity in vivo , 2018, The Journal of experimental medicine.

[6]  A. Zambrano,et al.  Physiological effects of amyloid precursor protein and its derivatives on neural stem cell biology and signaling pathways involved , 2019, Neural regeneration research.

[7]  Alzheimer's Association∗.  2019 Alzheimer's disease facts and figures , 2019, Alzheimer's & Dementia.

[8]  G. Glenner,et al.  Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. , 1984, Biochemical and biophysical research communications.

[9]  M. Bursavich,et al.  Gamma Secretase Modulators: New Alzheimer's Drugs on the Horizon? , 2016, Journal of medicinal chemistry.

[10]  J. Macor,et al.  Identification and Preclinical Evaluation of the Bicyclic Pyrimidine γ-Secretase Modulator BMS-932481 , 2019, ACS medicinal chemistry letters.

[11]  P. S. St George-Hyslop,et al.  Assembly of the presenilin γ‐/ε‐secretase complex , 2012, Journal of neurochemistry.

[12]  I. Sarkar,et al.  Origins of amyloid-β , 2013, BMC Genomics.

[13]  J. Kornhuber,et al.  Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation , 2002, Journal of neurochemistry.

[14]  D. Burnett,et al.  Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer’s disease , 2016, Alzheimer's Research & Therapy.